A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab
Tóm tắt
Crohn’s disease (CD) is a chronic and progressive disease in which the long-term management is important. This study sought to assess treatment persistence and dose escalation in the maintenance phase with adalimumab (ADA) or infliximab (IFX) in a Japanese real-world setting. A retrospective analysis was conducted using the Japan Medical Data Center database. CD patients with either ADA or IFX prescriptions between January 2012 and February 2015 were included. Outcomes of interest were (1) failure in the induction phase (defined as switch or discontinuation) and (2) persistence in the maintenance phase (defined as the absence of switch or discontinuation over 12 months since maintenance initiation). Overall, 133 patients (53 ADA; 80 IFX) were included. Of them, treatment failed in 26 patients (19.6%) in the induction phase. During the induction phase, there was a trend towards fewer treatment failures with ADA than IFX (88.7% vs. 75.0%; p = 0.051). Of those who completed induction, 64 patients (33 ADA; 31 IFX) had at least 12 months of valid insurance enrolment after the initiation of maintenance and 13 (5 ADA; 8 IFX) had either switch or discontinuation within 12 months after the initiation of maintenance. Probabilities of switch or discontinuation over 12 months after the maintenance date were 15.2% and 20.9% for ADA and IFX groups, respectively (p-log rank = 0.7764). Japanese patients have a high primary response to anti-tumor necrosis factor therapy in the real-world setting, in line with the results of clinical trials. This initial therapeutic advantage can be lost during the maintenance phase, leading to dose escalation, treatment switch, or discontinuation. This study suggests that those events occurred in comparable proportions of patients treated with either ADA or IFX. However, these findings should be considered with caution given the retrospective nature and small size of the study. Abbvie GK, Tokyo, Japan.
Tài liệu tham khảo
Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42 (quiz e30).
Nakano T, et al. Inflammatory bowel disease, epidemiology. Seijinbyo to Seikatsushukanbyo. 2014;44(3):251–5.
Ueno F, et al. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013;48(1):31–72.
Manz M, et al. Therapy of steroid-resistant inflammatory bowel disease. Digestion. 2012;86(Suppl 1):11–5.
Summers RW, et al. National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847–69.
Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn’s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012;18(12):2225–31.
Hanauer SB, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.
Colombel JF, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
Hanauer SB, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33 (quiz 591).
Sandborn WJ, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–9.
Ogata H, et al. Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn’s disease. J Crohns Colitis. 2016;10(9):1033–41.
Watanabe M, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6(2):160–73.
Watanabe M, et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn’s disease. J Crohns Colitis. 2014;8(11):1407–16.
Dupont-Lucas C, et al. Identifying patients at high risk of loss of response to infliximab maintenance therapy in paediatric Crohn’s disease. J Crohns Colitis. 2016;10(7):795–804
Gonzaga JE, et al. Durability of infliximab in Crohn’s disease: a single-center experience. Inflamm Bowel Dis. 2009;15(12):1837–43.
Ma C, et al. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn’s disease. Aliment Pharmacol Ther. 2014;40(9):1044–55.
O’Donnell S, et al. Higher rates of dose optimisation for infliximab responders in ulcerative colitis than in Crohn’s disease. J Crohns Colitis. 2015;9(10):830–6.
Qazi T, et al. The tolerability and efficacy of rapid infliximab infusions in patients with inflammatory bowel disease. Dig Dis Sci. 2016;61(2):589–96.
Regueiro M, et al. Infliximab dose intensification in Crohn’s disease. Inflamm Bowel Dis. 2007;13(9):1093–9.
Rosh JR, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol. 2009;104(12):3042–9.
Swaminath A, et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment Pharmacol Ther. 2009;29(3):273–8.
Viazis N, et al. Azathioprine discontinuation earlier than 6 months in Crohn’s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Eur J Gastroenterol Hepatol. 2015;27(4):436–41.
Vermeire S, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease. Am J Gastroenterol. 2002;97(9):2357–63.
Komiyama T, et al. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohns Colitis. 2008;2(4):315–21.
Kakuta Y, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2016;16(3):280–5.
The medical procedure index. Health Service Bureau, Ministry of Health, Labor and Welfare.; http://www.iryohoken.go.jp/shinryohoshu/downloadMenu/. Accessed 10 June 2016.
Schnitzler F, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58(4):492–500.
Farkas K, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis—experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257–62.
Esposti LD, et al. Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study. Clinicoecon Outcomes Res. 2014;6:401–7.
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–95.
Peyrin-Biroulet L, et al. Anti-TNF monotherapy for Crohn’s disease: a 13-year multicentre experience. J Crohns Colitis. 2016;10(5):516–24.
IFX: Package insert (30th version) D21, REMICADE for I.V. Infusion100 August 2015 11th May, 2016]. http://www.info.pmda.go.jp/go/pack/2399402F1026_1_37/. Accessed 10 June 2016.
ADA: Package insert (20th version), HUMIRA subcutaneous infusion 20 mg/syringe 0.4 mL, 40 mg/syringe 0.8 mL. June 2015 11th May, 2016]; http://www.info.pmda.go.jp/go/pack/3999426G1024_2_07/. Accessed 10 June 2016.
Takatsu N, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2009;24(7):1258–64.
Colombel JF, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.
Ishige T, et al. Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in Japan. J Gastroenterol. 2010;45(9):911–7.
Takebayashi T. Descriptive epidemiology of inflammatory bowel disease in Japan. Nihon Rinsho. 2012;70(Suppl 1):39–43.
de Ridder L, et al. Infliximab dependency in pediatric Crohn’s disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14(3):353–8.